Summary •Bellus Health, Inc. (BLU.TO) is a company focused on the development of treatments for rare diseases. •The lead product candidate is Kiacta™, a drug candidate currently in a confirmatory Phase III trial for the treatment of AA Amyloidosis. •Bellus has an additional clinical stage compound in Shigamab™, a monoclonal antibody treatment for hemolytic uremic syndrome caused by Shiga-like toxin producing E. coli. •The company exited the first quarter 2014 with approximately CAD$14 million, which should enable Bellus to finance its operations beyond the end of the Kiacta™ Phase III trial. •We feel confident that the Phase III trial for Kiacta™ will be successful. We are initiating coverage with a Buy rating and $2.50 price target. Full Article - https://seekingalpha.com/article/2227263-an-in-depth-look-at-kiacta-yields-200-percent-upside-on-bellus-health